Standardization of antifungal susceptibility testing and clinical relevance

Medical Mycology, Supplement

Volumn 36, Issue 1, 1998, Pages 68-78

  Espinel Ingroff, A ^a   Barchiesi, F ^b   Hazen, K C ^c   Martinez Suarez, J V ^d   Scalise, G ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF VIRGINIA   (United States)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antifungal testing; Relevance of standard methods

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TERBINAFINE;

AGAR GEL DIFFUSION; ANTIBIOTIC SENSITIVITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CULTURE MEDIUM; LABORATORY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; STANDARDIZATION;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, MICROBIAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; QUALITY CONTROL;

EID: 0032311207     PISSN: 09668454     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (80)

1. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-25.
2. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-78.
3. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management. Clin Infect Dis 1993; 17: S487-S91.
4. Galgiani JN, Reiser J, Brass C, Espinel-Ingroff A, Gordon MA, Kerkering TM. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother 1987; 31: 1343-7.
5. Powderly WG. Therapy for cryptococcal meningitis in patients with AIDS. Clin Infec Dis 1992; 1 (Suppl. 14): S54-9.
6. Galgiani JN, Catanzaro A, Cloud GA et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993; 119: 28-35.
7. Dismukes WE, Bradsher RW, Cloud GA et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93: 489-97.
8. Graybill JR, Stevens DA, Galgiani JN et al. Itraconazole treatment of coccidioidomycosis. Am J Med 1990; 89: 282-90.
9. Denning DW, Lee JY, Hostetler JS et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy of invasive aspergillosis. Am J Med 1994; 97: 135-44.
10. Sharkey-Mathis PK et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279-85.
11. Espinel-Ingroff A, Kauffman CA, Graybill JR et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1992; 30: 3138-45.
12. Fromtling RA, Galgiani JN, Pfaller MA et al. 1993. Multicenter evaluation of a macrobroth antifungal susceptibility test for yeasts. Antimicrob Agents Chemother 1993; 37: 39-45.
13. National Committee for Clinical Laboratory Standards. 1992 Reference method for broth dilution susceptibility testing of yeasts; Proposed Standard. NCCLS document M27-P (ISBM 1-56238-186-5). NCCLS, 771 E. Lancaster Avenue, Villanova, PA, 19085.
14. National Committee for Clinical Laboratory Standards. 1995 Reference method for broth dilution antifungal susceptibility testing of yeasts; Tentative standard. NCCLS document M27-T. NCCLS, 771 E. Lancaster Avenue, Villanova, PA, 19085.
15. National Committee for Clinical Laboratory Standards. 1997 Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard. NCCLS document M27-T. NCCLS, 771 E. Lancaster Avenue, Villanova, PA, 19085.
16. Espinel-Ingroff A. Antifungal susceptibility testing. Clin Microbiol Newsl 1996; 18: 161-8.
17. Espinel-Ingroff A, Pfaller M. Antifungal agents and susceptibility testing. In: Murray PK, Baron EJ, Pfaller MA. Tenover FC, Yolken RH, eds Manual of Clinical Microbiology, 6th edn. American Society for Microbiology. Washington, DC 1995: 1405-21.
18. Rex J, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole. itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-7.
19. Espinel-Ingroff A. Clinical relevance of antifungal resistance. Infect Dis Clin North America 1997; 11: 929-44.
20. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
21. Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG, Cooper CR, McGinnis MR. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol 1995; 33: 1104-7.
22. Rex JH, Pfaller MA, Lancaster M, Odds FC, Bolmström A, Rinaldi MG. Quality control guidelines for National Committee for Clinical Laboratory Standards-recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol 1996; 34: 816-7.
23. Stiller RL, Bennett JE, Scholer HJ, Wall M, Polak A, Stevens DA. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis 1983; 147: 1070-7.
24. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV infected patients. Eur J Clin Microbiol Infect Dis 1993; 12: 911-5.
25. Pfaller MA, DuPont B, Kobayashi GS, Müller J, Rinaldi MG, Espinel-Ingroff A, Shadomy S, Troke PF, Walsh TJ, Warnock DW. Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother 1992; 36: 1805-9.
26. Laguna F, Rodríguez-Tudela JL, Martínez-Suárez JV, Polo R, Valencia E, Díaz-Guerra TM, Dronda F. Patterns of fluconazole susceptibility of oropharyngeal candidiasis in isolates from human immuno-deficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis 1997; 24: 124-30.
27. Espinel-Ingroff A. E test for antifungal susceptibility testing of yeasts. Diagn Microbiol Infect Dis 1994; 19: 217-20.
28. Sewell DL, Pfaller MA, Barry AL. Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol 1994; 32: 2099-102.
29. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for azoie antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-40.
30. Chen SCA, O'Donnell ML, Gordon S, Gilbert GL. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique J Antimicrob Chemother 1996; 37: 265-73.
31. Rodríguez-Tudela JL, Martínez-Suárez JV. Improved medium for fluconazole susceptibility testing of Candida albicans. Antinucrob Agents Chemother 1994; 38: 45-8.
32. Ghannoum MA, Ibrahim AS, Fu Y, Shafiq MC, Edwards JE, Criddle RS. Susceptibility testing of Cryptococcus neoformans' a microdilution technique. J Clin Microbiol 1992; 30: 2881-6.
33. Rodríguez-Tudela JL, Martínez-Suárez JV. Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. J Antimicrob Chemother 1995; 35: 793-804.
34. Sanati H, Messer SA, Pfaller M, Witt M, Larsen R, Espinel-Ingroff A, Ghannoum M. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol 1996; 34: 1280-2.
35. Rex JH, Cooper CR, Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906-9.
36. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520-2.
37. Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN. An interlaboratory evaluation of the E test method for antifungal susceptibility testing of pathogenic yeasts for five antifungal agents using casitone agar and solidified RPMI 1640 with 2% glucose. J Clin Microbiol 1996; 38: 848-52.
38. Ruhnke M, Schmidt-Westhausen A, Engelmann E, Trautmann M. Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy. J Clin Microbiol 1996; 34: 3208-11.
39. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993; 6: 367-81.
40. Martínez-Suárez JV, Rodríguez-Tudela JL. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother 1996; 40: 1277-9.
41. Anaissie E, Paetznick V, Bodey GP. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother 1991; 35: 1641-6.
42. Pfaller MA, Messer SA, Coffmann S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870. J Clin Microbiol 1995; 33: 1094-7.
43. Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for research automation. Antimicrob Agents Chemother 1995; 39: 2051-60.
44. Telher R, Krajden M, Grigoriew GA, Campbell I. Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother 1992; 36: 1619-25.
45. Fournier C, Gaspar A, Bordlot F, Villard J. Evaluation of a broth microdilution antifungal susceptibility test with a pH indicator: comparison with the broth macrodilution procedures. J Antimicrob Chemother 1995; 35: 373-80.
46. Pfaller MA, Barry AL. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1994; 32: 1992-6.
47. Pfaller MA, Grant C, Morthland V, Rhine-Chalberg J. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J Clin Microbiol 1994; 32: 506-9.
48. Tiballi RN, He X, Zarins LT, Revankar SG, Kauffman CA. Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol 1995; 33: 915-7.
49. To W, Fothergill AW, Rinaldi MG. Comparative evaluation of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1995; 33: 2660-4.
50. Espinel-Ingroff A, Rodríguez-Tudela JL, Martínez-Suárez JV. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J Clin Microbiol 1995; 33: 3154-8.
51. Rodríguez-Tudela JL, Berenguer J, Martínez-Suárez JV, Sánchez R. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrob Agents Chemother 1996; 40: 1998-2003.
52. Odds FC, DeBacker T, Dams G, Vranckx L, Woestenborghs F. Oxygen as limiting nutrient for growth of Cryptococcus neoformans. J Clin Microbiol 1995; 33: 995-7.
53. Hacek DM, Noskin GA, Trakas K, Peterson LR. Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory. J Clin Microbiol 1995; 33: 1884-9
54. Odds FC. Effects of temperature on anti-Candida activities of antifungal antibiotics. Antimicrob Agents Chemother 1993; 37: 685-91.
55. Barchiesi F, Hollis RJ, McGough DA, Scahsc G, Rinaldi MG. Pfaller MA. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Inject Dis 1995; 20: 634-40.
56. Redding S, Smith J, Farinacci G, Fothergill A, Rhine-Chalberg J, Pfaller M Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in patients with AIDS. documentation of in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240-2.
57. Rodriguez-Tudela JL, Martinez-Suarez JV, Dronda F, Laguna F, Chaves F, Valencia E. Correlation of in vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antunicrob Chemother 1995; 35: 793-804.
58. Espinel-Ingroff A, Quart A, Steele-Moore L, Metcheva I, Buck GA, Bruzzese VL, Reich D. Molecular karyotyping of multiple yeast species isolated from nine patients with AIDS during prolonged fluconazole therapy. J Med Vet Mycol 1996; 34: 111-6.
59. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non neutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-4.
60. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 2495-7.
61. Guennec RL, Reynes J, Mallie M, Pujol C, Janbon F, Bastide J-M. Fluconazole- and itraconazole resistant Candida albicans strains from AIDS patients: Multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol 1995; 33: 2732-7.
62. Holt RJ, Azmi A. Miconazole-resistant Candida. Lancet 1978; i: 50-1.
63. Horsburgh CR, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazolc: experience with twenty-one patients. Am J Med 1983; 74: 23-9.
64. Smith KJ, Warnock DW, Kennedy CTC, Johnson FM, Hopwood V, Van Cutsem J, Vanden Bossche H. Azole resistance in Candida albicans. J Med Vet Mycol 1986; 24: 133-44.
65. Warnock DW, Johnson BM, Richardson MD, Vickers CFH. Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet 1983; I: 642-3.
66. Merz WG, Sandford GR. Isolation and characterization of a polyene-resistant variation of Candida tropicalis. J Clin Microbiol 1979; 9: 677-80.
67. Merz WG. Candida Iusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984; 20: 1194-5.
68. Pappagianis D, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida Iusitaniae infecting a human. Antimicrob Agents Chemother 1979; 16: 123-6.
69. Woods RA, Bard M, Jackson IE, Drutz DJ Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J Infect Dis 1974; 129: 53-8.
70. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotencin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988; 84: 826-32.
71. Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993; 37: 1383-6.
72. Martin JW, Fothergill AW, Rinaldi MG. Antifungal susceptibility testing of pathogenic moulds: effects of germination on the outcome of in vitro susceptibility to amphotericin B and itraconazole. Intersc Conf on Antimicrob Agents Chemother 1992; 479: 179.
73. Granade TC, Artis WM. Antimycotic susceptibility testing of dermatophytes in microcultures with standardized fragmented mycelial inoculum. Antimicrob Agents Chemother 1980; 17: 725-9.
74. Yamada H, Kohno S, Maesaki S, Koga H, Kaku M, Hara K, Tanaka H. Rapid and highly reproducible method for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 1993; 31: 1009-12.
75. Alvarez M, Ponga BL, Rayon C, Gala JG, Porto MCR, Gonzalez M, Martinez-Suarez JV, Rodriguez-Tudela JL. Nosocomial outbreak caused by Scedosporium prolificans (inflatum): four fatal cases in leukemic patients. J Clin Microbiol 1995; 33: 3290-5.
76. Reuben A, Anaissie E, Nelson PE, Hashem R, Legrand C, Ho DH, Bodey GP. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother 1989; 33: 1647-9
77. Gehrt A, Peter J, Pizzo PA, Walsh TJ. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol 1995; 33: 1302-7.
78. Espinel-Ingroff A, Dawson K, Pfaller H et al. Comparative and collaborative evaluation of standardization antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995: 39; 314-9.
79. Espinel-Ingroff A, Bowden R, Meneses P et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Antimicrobial Agents Chemother 1997; 35: 139-43.
80. Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal models. Antimicrob Agents Chemother 1998; 42: 282-8.